The live attenuated influenza vaccine (LAIV) is preferentially recommended for use in most children yet remains unsafe for the groups most at risk. Here we have improved the safety of a mouse-adapted live attenuated influenza vaccine containing the same attenuating amino acid mutations as in human LAIV by adding an additional mutation at PB1 residue 319. This results in a vaccine with a 20-fold decrease in protective efficacy and a 10,000-fold increase in safety.
T
he live attenuated influenza vaccine (LAIV) is preferentially recommended for use in most children and has outperformed its inactivated rival in recent clinical trials (1) . However, this vaccine is not approved for use in children under 2 years of age or asthmatics due to safety concerns in the initial licensure trials (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . In pursuit of a safer vaccine, we previously developed an experimental animal (mouse) model to study the safety and immunogenicity of LAIV by introducing the attenuating mutations of LAIV (PB2 N265S; PB1 K391E, D581G, and A661T) (Fig. 1A) into the genetic background of the mouse-adapted, highly virulent influenza A virus (IAV) strain, A/PR/8/34 (PR8). This resulted in a modified LAIV that retained virulence in C57BL/6 (B6) mice, such that it is possible to identify additional attenuating mutations that further reduce the virulence of this virus (12) . Here we extend that work and show that adding a mutation at residue 319 of PB1 conveys a dramatic safety increase with only a modest decrease in immunogenicity.
We replaced the natural (and universally conserved) leucine with glutamine at residue 319 of PB1 (Fig. 1A) . This amino acid lies underneath the PA linker region and 30 Å from PB1 residue 391 (the nearest amino acid mutation of LAIV) (13) . Mutating PB1 position 319 from leucine to glutamine in the context of the mutations of LAIV results in a dramatically altered polymerase activity profile as measured by the minigenome assay (Fig. 1B) , as PR8 LAIV containing 319Q shows a sharp reduction in polymerase activity at temperatures as low as 37°C. Interestingly, the introduction of PB1 L319Q alone has little to no impact on temperature-sensitive polymerase activity.
We then rescued viruses containing either PB1 L319Q (PR8 319Q) alone or the attenuating mutations of LAIV and PB1 319Q (PR8 LAIV 319Q) and analyzed their growth in MDCK, A549, and Vero cells. A549 cells were selected because they are derived from the human airway, while Vero cells were chosen because they have a defective interferon response system (14) (15) (16) (17) (18) .
Compared to wild-type (WT) viruses, PR8 containing only PB1 L319Q shows a slight reduction in replication at elevated temperatures in A549 cells, but not in MDCK or Vero cells (Fig.  1 ). PR8 LAIV shows impaired growth at 39°C in all cell types tested (12) . In contrast, PR8 LAIV 319Q shows dramatically reduced replication at 37°C, and no virus was detected at 39°C in A549 and MDCK cells. Therefore, the addition of PB1 319Q dramatically increases the temperature sensitivity of viruses containing the attenuating mutation of LAIV. We also examined the stability of these viruses and saw that the viruses retained the attenuating mutations after 10 passages in tissue culture (data not shown).
We then sought to examine the safety of these viruses in mice. Five-to 7-week-old female B6 mice (Jackson Laboratory) were infected intranasally after light anesthetization with increasing doses of PR8 319Q and PR8 LAIV 319Q. Data from Cox et al. on the safety of LAIV in C57BL/6 mice is replicated for comparison (12) . Addition of PB1 319Q to LAIV increased safety by 10,000-fold (from 10 2 focus-forming units [FFU] to 10 6 FFU), as determined by comparing maximum safe doses in mice (i.e., the maximum dose at which no weight loss was observed), as PR8 LAIV has a maximum safe dose of 100 FFU ( Fig. 2 and Table 1 ). This 10,000-fold increase in safety over LAIV alone is accompanied by a slight (20-fold) increase in the vaccine dose needed for protection from lethal challenge ( Fig. 2 and Table 1) .
Virus replication was detected in the mouse lung with doses of 10 7 FFU resulting in viral titers of 3 ϫ 10 4 and 10 5 FFU on days 2 and 4 postinfection, respectively (Fig. 3A) . These viruses were sequenced, and no reversion mutants were detected (data not shown). No virus was recovered from the lungs of mice infected with doses of 10 6 FFU or lower at 2, 3, or 4 days postinfection (data not shown).
The greatly increased attenuation of PR8 LAIV 319Q prompted us to question whether this virus was immunogenic and in fact replicating in these mice at safe doses. We performed hemagglutination inhibition (HAI) assays on mouse sera collected 15 days postinfection. All mice infected with doses of 10 4 , 10 5 , and 10 6 FFU seroconverted as measured by the HAI assay (Fig. 3B) . One mouse infected with 10 3 FFU of PR8 LAIV 319Q seroconverted, but no mice infected with 10 2 FFU did. Notably, the maximum nonlethal dose of PR8 LAIV 319Q (10 6 FFU) elicited 4-fold-higher titers of serum HAI antibodies compared to the maximum nonlethal dose of PR8 LAIV (10 4 FFU) (Fig. 3B) . We also included an additional control for replication. We UV inactivated PR8 LAIV 319Q for 20 min (on ice) and confirmed inactivation by plaque assay (data not shown). We then infected mice with this UV-inactivated virus at 10 6 FFU (as determined before UV inactivation). Mice were bled, and sera were analyzed in parallel with the above sera. These mice did not seroconvert, as assessed by HAI-nor did they exhibit detectable levels of HA binding serum antibodies, as measured by enzyme-linked immunosorbent assay (ELISA) (in contrast, mice vaccinated with 10 6 FFU of live LAIV 319Q showed robust HA binding past a 1:10,000 dilution as did the sera of mice infected with a nonlethal dose of WT PR8). These data suggest that seroconversion requires a rep- licating virus and that this novel LAIV is not functioning like a virus-like particle but is replicating in the host and that this replication is required for immunogenicity.
We then sought to examine the protective efficacy of this novel vaccine candidate. Mice were challenged with 100 50% lethal doses (LD 50 ) of either PR8 (homologous) or X31 (heterologous) virus 21 days after vaccination. Mice vaccinated with either phosphate-buffered saline (PBS) or 10 2 FFU of PR8 LAIV (the maximum safe dose) were included as negative and positive controls, respectively. LAIV 319Q provided greater protection than LAIV at matched doses of priming virus (the highest dose of each virus that did not cause weight loss), suggesting that this safer vaccine candidate does not have compromised efficacy (Fig. 4) . Additionally, LAIV 319Q protected mice against lethal challenge at vaccination doses of 10 3 or greater against both homologous and heterologous chal- lenges. This implicates T cell-mediated immunity, as none of these mice displayed seroconversion to X31 at day 15 postvaccination (data not shown). Interestingly, mice that did not seroconvert to either virus were also protected against homologous and heterologous challenge. This echoes the work of Halliley et al. who showed that measuring vaccine responses to LAIV by HAI misses protective efficacy (19) .
In summary, we have created a live candidate vaccine with 10,000-fold-increased safety that also retains robust immunogenicity in the murine model of influenza infection. The addition of PB1 L319Q may be considered for improving the safety of the current LAIV.
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